Key result
Naproxen shows no significant difference in major cardiovascular events versus placebo.
Non-significant CV risk signal warrants no practice change; leaves open need for adequately powered trials.
SEN is the principal investigator for a large clinical trial comparing cardiovascular event rates for three nonsteroidal antiinflammatory agents: naproxen, ibuprofen, and celecoxib.Although the study is
No takes yet. Share an insight, caveat, or question.
Steven E. Nissen (2006) conducted an editorial in Alzheimer's Disease. Naproxen vs. Placebo was evaluated on Composite of cardiovascular death, myocardial infarction, and stroke (HR 1.57, 95% CI 0.87-2.81, p=0.13). Naproxen compared with placebo showed a non-significant hazard ratio of 1.57 for cardiovascular death, myocardial infarction, and stroke in the prematurely terminated ADAPT trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: